MarginsXMarginsX
Home › Markets › Health Care › BDSX

Biodesix Inc. (BDSX)

BDSX trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.00
-8.91% on the day
Market cap
$99.8M
Micro cap
Revenue · 2025
$88.5M
+24.1% on 2024
Net income · 2025
-$35.3M
-39.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/0001193125-26-076547-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBDSX on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO year2020
SEC CIK0001439725
SEC industry codeServices-Medical Laboratories
Incorporated inDE

Financials · 2025

LineValue
Revenue$88.5M
Net income-$35.3M
Operating income-$27.9M
Net margin-39.8%
Operating margin-31.5%
Revenue growth+24.1%
Cash$19.0M
Total assets$87.5M
P/E (computed)Net income was not positive
P/S (computed)1.1×

Warning signs

Cash runway
18.8 months
$28.4M cash at September 30, 2026
Share count, 1 year
+39.4%
2025-10-28 to 2026-10-30 · +145.1% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$28.4M cash; operating cash flow -$4.5M a quarter.Report 2026-09-30
Shares outstanding11,088,511 (2026-10-30); 7,955,685 a year earlier; 90,476,295 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-10-30
Reverse splits, 3 years1; latest 1-for-20 on 2025-09-15Source 2025-09-15
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Denver, Colorado, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.1M, sold $107K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$24.0M-$8.0M-$7.2M$28.4M$50.0M$105.2M10-Q 2026-11-05
Q2 2026
2026-06-30
$26.9M-$7.3M-$1.6M$30.0M$50.0M$102.9M10-Q 2026-08-05
Q1 2026
2026-03-31
$25.6M-$7.8M-$10.2M$25.6M$50.0M$96.1M10-Q 2026-05-04
Q4 2025
2025-12-31
$28.8M-$4.0M$778K$19.0M$50.0M$88.5M10-K 2026-02-26
Q3 2025
2025-09-30
$21.8M-$8.7M-$8.9M$16.6M$50.0M$80.2M10-Q 2026-11-05
Q2 2025
2025-06-30
$20.0M-$11.5M-$6.6M$20.7M$50.0M$76.6M10-Q 2026-08-05
Q1 2025
2025-03-31
$18.0M-$11.1M-$8.6M$17.6M$40.0M$74.5M10-Q 2026-05-04
Q4 2024
2024-12-31
$20.4M-$8.3M-$4.1M$26.2M$40.0M$71.3M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-06-01
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 602 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+15.8%
1 month-60.5%
3 months-58.5%
Year to date+45.3%
1 year+25.1%
From 52-week high-67.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
KEQUKewaunee Scientific Corporation$35.05-1.81%$101.5M
XGNExagen Inc.$3.77-8.72%$96.2M
SERASera Prognostics Inc.$1.94-3.48%$77.2M
BNRBurning Rock Biotech Limited$12.74-4.43%$134.4M
TLSITriSalus Life Sciences Inc.$2.27-6.58%$140.1M
YDESYD Bio Limited$4.83-1.02%$342.1M
FLGTFulgent Genetics Inc.$24.07-2.37%$672.6M
MDXHMDxHealth SA$0.1490+3.40%$14.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier